PubMed:12107080 JSONTXT

Annnotations TAB JSON ListView MergeView

    Glycosmos6-MAT

    {"project":"Glycosmos6-MAT","denotations":[{"id":"T1","span":{"begin":69,"end":76},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T2","span":{"begin":194,"end":201},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T3","span":{"begin":316,"end":323},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T4","span":{"begin":462,"end":469},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T5","span":{"begin":502,"end":509},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T6","span":{"begin":1568,"end":1575},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T7","span":{"begin":1902,"end":1909},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlycoBiology-FMA

    {"project":"GlycoBiology-FMA","denotations":[{"id":"_T1","span":{"begin":69,"end":76},"obj":"FMAID:14543"},{"id":"_T2","span":{"begin":69,"end":76},"obj":"FMAID:104231"},{"id":"_T3","span":{"begin":194,"end":201},"obj":"FMAID:104231"},{"id":"_T4","span":{"begin":194,"end":201},"obj":"FMAID:14543"},{"id":"_T5","span":{"begin":316,"end":323},"obj":"FMAID:104231"},{"id":"_T6","span":{"begin":316,"end":323},"obj":"FMAID:14543"},{"id":"_T7","span":{"begin":331,"end":338},"obj":"FMAID:256050"},{"id":"_T8","span":{"begin":462,"end":469},"obj":"FMAID:14543"},{"id":"_T9","span":{"begin":462,"end":469},"obj":"FMAID:104231"},{"id":"_T10","span":{"begin":462,"end":476},"obj":"FMAID:207543"},{"id":"_T11","span":{"begin":462,"end":476},"obj":"FMAID:104911"},{"id":"_T12","span":{"begin":462,"end":476},"obj":"FMAID:202967"},{"id":"_T13","span":{"begin":462,"end":476},"obj":"FMAID:104914"},{"id":"_T14","span":{"begin":470,"end":476},"obj":"FMAID:85355"},{"id":"_T15","span":{"begin":470,"end":476},"obj":"FMAID:261267"},{"id":"_T16","span":{"begin":502,"end":509},"obj":"FMAID:14543"},{"id":"_T17","span":{"begin":502,"end":509},"obj":"FMAID:104231"},{"id":"_T18","span":{"begin":767,"end":772},"obj":"FMAID:68646"},{"id":"_T19","span":{"begin":767,"end":772},"obj":"FMAID:169002"},{"id":"_T20","span":{"begin":1015,"end":1031},"obj":"FMAID:196731"},{"id":"_T21","span":{"begin":1015,"end":1031},"obj":"FMAID:82742"},{"id":"_T22","span":{"begin":1219,"end":1235},"obj":"FMAID:196731"},{"id":"_T23","span":{"begin":1219,"end":1235},"obj":"FMAID:82742"},{"id":"_T24","span":{"begin":1412,"end":1417},"obj":"FMAID:198663"},{"id":"_T25","span":{"begin":1433,"end":1435},"obj":"FMAID:272963"},{"id":"_T26","span":{"begin":1466,"end":1470},"obj":"FMAID:198663"},{"id":"_T27","span":{"begin":1568,"end":1575},"obj":"FMAID:14543"},{"id":"_T28","span":{"begin":1568,"end":1575},"obj":"FMAID:104231"},{"id":"_T29","span":{"begin":1568,"end":1582},"obj":"FMAID:104914"},{"id":"_T30","span":{"begin":1568,"end":1582},"obj":"FMAID:202967"},{"id":"_T31","span":{"begin":1568,"end":1582},"obj":"FMAID:207543"},{"id":"_T32","span":{"begin":1568,"end":1582},"obj":"FMAID:104911"},{"id":"_T33","span":{"begin":1576,"end":1582},"obj":"FMAID:85355"},{"id":"_T34","span":{"begin":1576,"end":1582},"obj":"FMAID:261267"},{"id":"_T35","span":{"begin":1673,"end":1679},"obj":"FMAID:261267"},{"id":"_T36","span":{"begin":1673,"end":1679},"obj":"FMAID:85355"},{"id":"_T37","span":{"begin":1902,"end":1909},"obj":"FMAID:104231"},{"id":"_T38","span":{"begin":1902,"end":1909},"obj":"FMAID:14543"}],"namespaces":[{"prefix":"FMAID","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    uniprot-human

    {"project":"uniprot-human","denotations":[{"id":"T1","span":{"begin":53,"end":64},"obj":"http://www.uniprot.org/uniprot/Q8NCG5"},{"id":"T2","span":{"begin":859,"end":870},"obj":"http://www.uniprot.org/uniprot/Q8NCG5"},{"id":"T3","span":{"begin":1393,"end":1404},"obj":"http://www.uniprot.org/uniprot/Q8NCG5"},{"id":"T4","span":{"begin":1454,"end":1465},"obj":"http://www.uniprot.org/uniprot/Q8NCG5"},{"id":"T5","span":{"begin":872,"end":885},"obj":"http://www.uniprot.org/uniprot/Q8NCG5"},{"id":"T6","span":{"begin":887,"end":891},"obj":"http://www.uniprot.org/uniprot/Q8NCG5"},{"id":"T7","span":{"begin":896,"end":901},"obj":"http://www.uniprot.org/uniprot/Q8NCG5"},{"id":"T8","span":{"begin":872,"end":875},"obj":"http://www.uniprot.org/uniprot/O14777"},{"id":"T9","span":{"begin":896,"end":899},"obj":"http://www.uniprot.org/uniprot/Q86UG4"},{"id":"T10","span":{"begin":1121,"end":1124},"obj":"http://www.uniprot.org/uniprot/Q86UG4"},{"id":"T11","span":{"begin":1094,"end":1105},"obj":"http://www.uniprot.org/uniprot/Q9GZS9"},{"id":"T12","span":{"begin":1651,"end":1662},"obj":"http://www.uniprot.org/uniprot/Q9GZS9"},{"id":"T13","span":{"begin":1106,"end":1117},"obj":"http://www.uniprot.org/uniprot/Q9GZS9"},{"id":"T14","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/P10266"},{"id":"T15","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/P63132"},{"id":"T16","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/P63133"},{"id":"T17","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/P63135"},{"id":"T18","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/P63136"},{"id":"T19","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/Q9BXR3"},{"id":"T20","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/Q9UQG0"},{"id":"T21","span":{"begin":1433,"end":1435},"obj":"http://www.uniprot.org/uniprot/Q9WJR5"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    uniprot-mouse

    {"project":"uniprot-mouse","denotations":[{"id":"T1","span":{"begin":53,"end":64},"obj":"http://www.uniprot.org/uniprot/Q9R1I1"},{"id":"T2","span":{"begin":859,"end":870},"obj":"http://www.uniprot.org/uniprot/Q9R1I1"},{"id":"T3","span":{"begin":1393,"end":1404},"obj":"http://www.uniprot.org/uniprot/Q9R1I1"},{"id":"T4","span":{"begin":1454,"end":1465},"obj":"http://www.uniprot.org/uniprot/Q9R1I1"},{"id":"T5","span":{"begin":872,"end":885},"obj":"http://www.uniprot.org/uniprot/Q9R1I1"},{"id":"T6","span":{"begin":887,"end":891},"obj":"http://www.uniprot.org/uniprot/Q9R1I1"},{"id":"T7","span":{"begin":896,"end":901},"obj":"http://www.uniprot.org/uniprot/Q9R1I1"},{"id":"T8","span":{"begin":1094,"end":1105},"obj":"http://www.uniprot.org/uniprot/Q9QUP4"},{"id":"T9","span":{"begin":1651,"end":1662},"obj":"http://www.uniprot.org/uniprot/Q9QUP4"},{"id":"T10","span":{"begin":1106,"end":1117},"obj":"http://www.uniprot.org/uniprot/Q9QUP4"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlycoBiology-NCBITAXON

    {"project":"GlycoBiology-NCBITAXON","denotations":[{"id":"T1","span":{"begin":331,"end":338},"obj":"http://purl.bioontology.org/ontology/STY/T024"},{"id":"T2","span":{"begin":767,"end":772},"obj":"http://purl.bioontology.org/ontology/STY/T025"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GO-BP

    {"project":"GO-BP","denotations":[{"id":"T1","span":{"begin":117,"end":125},"obj":"http://purl.obolibrary.org/obo/GO_0051923"},{"id":"T2","span":{"begin":145,"end":153},"obj":"http://purl.obolibrary.org/obo/GO_0051923"},{"id":"T3","span":{"begin":365,"end":367},"obj":"http://purl.obolibrary.org/obo/GO_0004306"},{"id":"T4","span":{"begin":1377,"end":1388},"obj":"http://purl.obolibrary.org/obo/GO_0006351"},{"id":"T5","span":{"begin":1636,"end":1646},"obj":"http://purl.obolibrary.org/obo/GO_0006351"},{"id":"T6","span":{"begin":1433,"end":1435},"obj":"http://purl.obolibrary.org/obo/GO_0003964"},{"id":"T7","span":{"begin":1466,"end":1484},"obj":"http://purl.obolibrary.org/obo/GO_0010467"},{"id":"T8","span":{"begin":1889,"end":1898},"obj":"http://purl.obolibrary.org/obo/GO_0065007"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GO-CC

    {"project":"GO-CC","denotations":[{"id":"T1","span":{"begin":767,"end":772},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    UBERON-AE

    {"project":"UBERON-AE","denotations":[{"id":"T1","span":{"begin":69,"end":76},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T2","span":{"begin":194,"end":201},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T3","span":{"begin":316,"end":323},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T4","span":{"begin":462,"end":469},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T5","span":{"begin":502,"end":509},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T6","span":{"begin":1568,"end":1575},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T7","span":{"begin":1902,"end":1909},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"T8","span":{"begin":331,"end":338},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"T9","span":{"begin":462,"end":476},"obj":"http://purl.obolibrary.org/obo/UBERON_0000317"},{"id":"T10","span":{"begin":1568,"end":1582},"obj":"http://purl.obolibrary.org/obo/UBERON_0000317"},{"id":"T11","span":{"begin":470,"end":476},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"T12","span":{"begin":1576,"end":1582},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"T13","span":{"begin":1673,"end":1679},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    EDAM-topics

    {"project":"EDAM-topics","denotations":[{"id":"T1","span":{"begin":1377,"end":1388},"obj":"http://edamontology.org/topic_0110"},{"id":"T2","span":{"begin":1377,"end":1388},"obj":"http://edamontology.org/topic_3308"},{"id":"T3","span":{"begin":1377,"end":1388},"obj":"http://edamontology.org/topic_3512"},{"id":"T4","span":{"begin":1377,"end":1388},"obj":"http://edamontology.org/topic_0203"},{"id":"T5","span":{"begin":1377,"end":1392},"obj":"http://edamontology.org/topic_0749"},{"id":"T6","span":{"begin":1436,"end":1439},"obj":"http://edamontology.org/topic_0195"},{"id":"T7","span":{"begin":1466,"end":1484},"obj":"http://edamontology.org/topic_0203"},{"id":"T8","span":{"begin":1636,"end":1646},"obj":"http://edamontology.org/topic_3512"},{"id":"T9","span":{"begin":1636,"end":1646},"obj":"http://edamontology.org/topic_3308"},{"id":"T10","span":{"begin":1636,"end":1646},"obj":"http://edamontology.org/topic_0110"},{"id":"T11","span":{"begin":1636,"end":1646},"obj":"http://edamontology.org/topic_0203"},{"id":"T12","span":{"begin":1636,"end":1650},"obj":"http://edamontology.org/topic_0749"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    EDAM-DFO

    {"project":"EDAM-DFO","denotations":[{"id":"T1","span":{"begin":161,"end":169},"obj":"http://edamontology.org/data_1756"},{"id":"T2","span":{"begin":324,"end":330},"obj":"http://edamontology.org/operation_3435"},{"id":"T3","span":{"begin":455,"end":461},"obj":"http://edamontology.org/operation_3435"},{"id":"T4","span":{"begin":570,"end":578},"obj":"http://edamontology.org/operation_2423"},{"id":"T5","span":{"begin":819,"end":829},"obj":"http://edamontology.org/operation_2424"},{"id":"T6","span":{"begin":1352,"end":1364},"obj":"http://edamontology.org/data_1426"},{"id":"T7","span":{"begin":1352,"end":1364},"obj":"http://edamontology.org/operation_3630"},{"id":"T8","span":{"begin":1561,"end":1567},"obj":"http://edamontology.org/operation_3435"},{"id":"T9","span":{"begin":1666,"end":1672},"obj":"http://edamontology.org/operation_3435"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    NGLY1-deficiency

    {"project":"NGLY1-deficiency","denotations":[{"id":"PD-NGLY1-deficiency-B_T1","span":{"begin":24,"end":30},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T2","span":{"begin":154,"end":160},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T3","span":{"begin":250,"end":256},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T4","span":{"begin":632,"end":638},"obj":"chem:24139"},{"id":"PD-NGLY1-deficiency-B_T5","span":{"begin":735,"end":741},"obj":"chem:24139"}],"namespaces":[{"prefix":"hgnc","uri":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:"},{"prefix":"omim","uri":"https://www.omim.org/entry/"},{"prefix":"chem","uri":"https://pubchem.ncbi.nlm.nih.gov/compound/"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    DisGeNET5_gene_disease

    {"project":"DisGeNET5_gene_disease","denotations":[{"id":"12107080-0#53#64#gene10164","span":{"begin":53,"end":64},"obj":"gene10164"},{"id":"12107080-0#69#100#diseaseC0279639","span":{"begin":69,"end":100},"obj":"diseaseC0279639"},{"id":"12107080-9#42#53#gene10164","span":{"begin":1779,"end":1790},"obj":"gene10164"},{"id":"12107080-9#132#143#gene23563","span":{"begin":1869,"end":1880},"obj":"gene23563"},{"id":"12107080-9#69#92#diseaseC0007130","span":{"begin":1806,"end":1829},"obj":"diseaseC0007130"},{"id":"12107080-9#173#188#diseaseC0001418","span":{"begin":1910,"end":1925},"obj":"diseaseC0001418"},{"id":"12107080-9#69#92#diseaseC0007130","span":{"begin":1806,"end":1829},"obj":"diseaseC0007130"},{"id":"12107080-9#173#188#diseaseC0001418","span":{"begin":1910,"end":1925},"obj":"diseaseC0001418"}],"relations":[{"id":"53#64#gene1016469#100#diseaseC0279639","pred":"associated_with","subj":"12107080-0#53#64#gene10164","obj":"12107080-0#69#100#diseaseC0279639"},{"id":"42#53#gene1016469#92#diseaseC0007130","pred":"associated_with","subj":"12107080-9#42#53#gene10164","obj":"12107080-9#69#92#diseaseC0007130"},{"id":"42#53#gene10164173#188#diseaseC0001418","pred":"associated_with","subj":"12107080-9#42#53#gene10164","obj":"12107080-9#173#188#diseaseC0001418"},{"id":"42#53#gene1016469#92#diseaseC0007130","pred":"associated_with","subj":"12107080-9#42#53#gene10164","obj":"12107080-9#69#92#diseaseC0007130"},{"id":"42#53#gene10164173#188#diseaseC0001418","pred":"associated_with","subj":"12107080-9#42#53#gene10164","obj":"12107080-9#173#188#diseaseC0001418"},{"id":"132#143#gene2356369#92#diseaseC0007130","pred":"associated_with","subj":"12107080-9#132#143#gene23563","obj":"12107080-9#69#92#diseaseC0007130"},{"id":"132#143#gene23563173#188#diseaseC0001418","pred":"associated_with","subj":"12107080-9#132#143#gene23563","obj":"12107080-9#173#188#diseaseC0001418"},{"id":"132#143#gene2356369#92#diseaseC0007130","pred":"associated_with","subj":"12107080-9#132#143#gene23563","obj":"12107080-9#69#92#diseaseC0007130"},{"id":"132#143#gene23563173#188#diseaseC0001418","pred":"associated_with","subj":"12107080-9#132#143#gene23563","obj":"12107080-9#173#188#diseaseC0001418"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlycoBiology-MAT

    {"project":"GlycoBiology-MAT","denotations":[{"id":"T1","span":{"begin":69,"end":76},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T2","span":{"begin":194,"end":201},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T3","span":{"begin":316,"end":323},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T4","span":{"begin":462,"end":469},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T5","span":{"begin":502,"end":509},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T6","span":{"begin":1568,"end":1575},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"T7","span":{"begin":1902,"end":1909},"obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    sentences

    {"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":102,"end":217},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":218,"end":406},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":407,"end":612},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":613,"end":858},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":859,"end":1093},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1094,"end":1296},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1297,"end":1440},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1441,"end":1614},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1615,"end":1736},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1737,"end":1926},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"T2","span":{"begin":102,"end":217},"obj":"Sentence"},{"id":"T3","span":{"begin":218,"end":406},"obj":"Sentence"},{"id":"T4","span":{"begin":407,"end":612},"obj":"Sentence"},{"id":"T5","span":{"begin":613,"end":858},"obj":"Sentence"},{"id":"T6","span":{"begin":859,"end":1093},"obj":"Sentence"},{"id":"T7","span":{"begin":1094,"end":1296},"obj":"Sentence"},{"id":"T8","span":{"begin":1297,"end":1440},"obj":"Sentence"},{"id":"T9","span":{"begin":1441,"end":1614},"obj":"Sentence"},{"id":"T10","span":{"begin":1615,"end":1736},"obj":"Sentence"},{"id":"T11","span":{"begin":1737,"end":1926},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"T2","span":{"begin":102,"end":217},"obj":"Sentence"},{"id":"T3","span":{"begin":218,"end":406},"obj":"Sentence"},{"id":"T4","span":{"begin":407,"end":612},"obj":"Sentence"},{"id":"T5","span":{"begin":613,"end":858},"obj":"Sentence"},{"id":"T6","span":{"begin":859,"end":1093},"obj":"Sentence"},{"id":"T7","span":{"begin":1094,"end":1296},"obj":"Sentence"},{"id":"T8","span":{"begin":1297,"end":1440},"obj":"Sentence"},{"id":"T9","span":{"begin":1441,"end":1614},"obj":"Sentence"},{"id":"T10","span":{"begin":1615,"end":1736},"obj":"Sentence"},{"id":"T11","span":{"begin":1737,"end":1926},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    Lectin

    {"project":"Lectin","denotations":[{"id":"Lectin_T1","span":{"begin":368,"end":370},"obj":"https://acgg.asia/db/lfdb/LfDB0344"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlyTouCan-IUPAC

    {"project":"GlyTouCan-IUPAC","denotations":[{"id":"GlycanIUPAC_T1","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T2","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T3","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T4","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T5","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G26693XF\""},{"id":"GlycanIUPAC_T6","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T7","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T8","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T9","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T10","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G01864SU\""},{"id":"GlycanIUPAC_T11","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T12","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T13","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T14","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T15","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G17605FD\""},{"id":"GlycanIUPAC_T16","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T17","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T18","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T19","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T20","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G41950LU\""},{"id":"GlycanIUPAC_T21","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T22","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T23","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T24","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T25","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G57195RJ\""},{"id":"GlycanIUPAC_T26","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T27","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T28","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T29","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T30","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G85391SA\""},{"id":"GlycanIUPAC_T31","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T32","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T33","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T34","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T35","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G89565QL\""},{"id":"GlycanIUPAC_T36","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T37","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T38","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T39","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T40","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G80869MR\""},{"id":"GlycanIUPAC_T41","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T42","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T43","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T44","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T45","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G55978NL\""},{"id":"GlycanIUPAC_T46","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T47","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T48","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T49","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T50","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G54644LT\""},{"id":"GlycanIUPAC_T51","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T52","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T53","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T54","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T55","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G25694UG\""},{"id":"GlycanIUPAC_T56","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T57","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T58","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T59","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T60","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G25126RB\""},{"id":"GlycanIUPAC_T61","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T62","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T63","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T64","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T65","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G51848AD\""},{"id":"GlycanIUPAC_T66","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T67","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T68","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T69","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T70","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G94667GM\""},{"id":"GlycanIUPAC_T71","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T72","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T73","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T74","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T75","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G30124BO\""},{"id":"GlycanIUPAC_T76","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T77","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T78","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T79","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T80","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G82777EZ\""},{"id":"GlycanIUPAC_T81","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T82","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T83","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T84","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T85","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G10151YZ\""},{"id":"GlycanIUPAC_T86","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T87","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T88","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T89","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T90","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G17585ZM\""},{"id":"GlycanIUPAC_T91","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T92","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T93","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T94","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T95","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G04411CJ\""},{"id":"GlycanIUPAC_T96","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T97","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T98","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T99","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T100","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G38254HJ\""},{"id":"GlycanIUPAC_T101","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T102","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T103","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T104","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T105","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G75188FS\""},{"id":"GlycanIUPAC_T106","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T107","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T108","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T109","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T110","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G70374VG\""},{"id":"GlycanIUPAC_T111","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T112","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T113","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T114","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T115","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G45176LJ\""},{"id":"GlycanIUPAC_T116","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T117","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T118","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T119","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T120","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G30874VW\""},{"id":"GlycanIUPAC_T121","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T122","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T123","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T124","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T125","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G69333MI\""},{"id":"GlycanIUPAC_T126","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T127","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T128","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T129","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T130","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G10676XO\""},{"id":"GlycanIUPAC_T131","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T132","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T133","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T134","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T135","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G14843DJ\""},{"id":"GlycanIUPAC_T136","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T137","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T138","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T139","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T140","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G47546FR\""},{"id":"GlycanIUPAC_T141","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T142","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T143","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T144","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T145","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G73695ZM\""},{"id":"GlycanIUPAC_T146","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T147","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T148","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T149","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T150","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G31923TJ\""},{"id":"GlycanIUPAC_T151","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T152","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T153","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T154","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T155","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G60519EP\""},{"id":"GlycanIUPAC_T156","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T157","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T158","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T159","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T160","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G07933IA\""},{"id":"GlycanIUPAC_T161","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T162","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T163","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T164","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T165","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G40745NH\""},{"id":"GlycanIUPAC_T166","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T167","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T168","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T169","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T170","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G54496YV\""},{"id":"GlycanIUPAC_T171","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T172","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T173","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T174","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T175","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G62953SQ\""},{"id":"GlycanIUPAC_T176","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T177","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T178","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T179","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T180","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G70070AY\""},{"id":"GlycanIUPAC_T181","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T182","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T183","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T184","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T185","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G78792WC\""},{"id":"GlycanIUPAC_T186","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T187","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T188","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T189","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T190","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G25238AV\""},{"id":"GlycanIUPAC_T191","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T192","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T193","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T194","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T195","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G40510DP\""},{"id":"GlycanIUPAC_T196","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T197","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T198","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T199","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T200","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G61120TK\""},{"id":"GlycanIUPAC_T201","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T202","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T203","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T204","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T205","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G41342KV\""},{"id":"GlycanIUPAC_T206","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T207","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T208","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T209","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T210","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G90703NA\""},{"id":"GlycanIUPAC_T211","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T212","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T213","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T214","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T215","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G01591HR\""},{"id":"GlycanIUPAC_T216","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T217","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T218","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T219","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T220","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G56520XN\""},{"id":"GlycanIUPAC_T221","span":{"begin":24,"end":30},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T222","span":{"begin":154,"end":160},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T223","span":{"begin":250,"end":256},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T224","span":{"begin":632,"end":638},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T225","span":{"begin":735,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G81830JX\""},{"id":"GlycanIUPAC_T226","span":{"begin":722,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G03082CI\""},{"id":"GlycanIUPAC_T227","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G98309OP\""},{"id":"GlycanIUPAC_T228","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G65421WP\""},{"id":"GlycanIUPAC_T229","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G77738DZ\""},{"id":"GlycanIUPAC_T230","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G87323ZC\""},{"id":"GlycanIUPAC_T231","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G14419JG\""},{"id":"GlycanIUPAC_T232","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G60423RL\""},{"id":"GlycanIUPAC_T233","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G99080VN\""},{"id":"GlycanIUPAC_T234","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G57125PO\""},{"id":"GlycanIUPAC_T235","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G65670OQ\""},{"id":"GlycanIUPAC_T236","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G44967LM\""},{"id":"GlycanIUPAC_T237","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G22151IM\""},{"id":"GlycanIUPAC_T238","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G28912BK\""},{"id":"GlycanIUPAC_T239","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G33589DL\""},{"id":"GlycanIUPAC_T240","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G14559WY\""},{"id":"GlycanIUPAC_T241","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G28723CY\""},{"id":"GlycanIUPAC_T242","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G93924TT\""},{"id":"GlycanIUPAC_T243","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G25565DN\""},{"id":"GlycanIUPAC_T244","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G97215EV\""},{"id":"GlycanIUPAC_T245","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G79664KO\""},{"id":"GlycanIUPAC_T246","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G24107FU\""},{"id":"GlycanIUPAC_T247","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G09864UE\""},{"id":"GlycanIUPAC_T248","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G28032MC\""},{"id":"GlycanIUPAC_T249","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G28005UP\""},{"id":"GlycanIUPAC_T250","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G92708AT\""},{"id":"GlycanIUPAC_T251","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G73757UC\""},{"id":"GlycanIUPAC_T252","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G51062DM\""},{"id":"GlycanIUPAC_T253","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G05866BJ\""},{"id":"GlycanIUPAC_T254","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G87394FZ\""},{"id":"GlycanIUPAC_T255","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G03871NF\""},{"id":"GlycanIUPAC_T256","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G29377VE\""},{"id":"GlycanIUPAC_T257","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G33457CX\""},{"id":"GlycanIUPAC_T258","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G97368GU\""},{"id":"GlycanIUPAC_T259","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G18512EL\""},{"id":"GlycanIUPAC_T260","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G41137VS\""},{"id":"GlycanIUPAC_T261","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G30521NA\""},{"id":"GlycanIUPAC_T262","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G19388CD\""},{"id":"GlycanIUPAC_T263","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G53151FU\""},{"id":"GlycanIUPAC_T264","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G27105XC\""},{"id":"GlycanIUPAC_T265","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G91210VM\""},{"id":"GlycanIUPAC_T266","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G40841DE\""},{"id":"GlycanIUPAC_T267","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G71241HP\""},{"id":"GlycanIUPAC_T268","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G84636BJ\""},{"id":"GlycanIUPAC_T269","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G47905LJ\""},{"id":"GlycanIUPAC_T270","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G39340DV\""},{"id":"GlycanIUPAC_T271","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G48801AQ\""},{"id":"GlycanIUPAC_T272","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G14573NX\""},{"id":"GlycanIUPAC_T273","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G56762TR\""},{"id":"GlycanIUPAC_T274","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G20013XO\""},{"id":"GlycanIUPAC_T275","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G39504DR\""},{"id":"GlycanIUPAC_T276","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G35218RQ\""},{"id":"GlycanIUPAC_T277","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G53048SH\""},{"id":"GlycanIUPAC_T278","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G78418IX\""},{"id":"GlycanIUPAC_T279","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G09780OD\""},{"id":"GlycanIUPAC_T280","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G56359GL\""},{"id":"GlycanIUPAC_T281","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G78941YC\""},{"id":"GlycanIUPAC_T282","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G26829FC\""},{"id":"GlycanIUPAC_T283","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G88538ZC\""},{"id":"GlycanIUPAC_T284","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G46593ZR\""},{"id":"GlycanIUPAC_T285","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G43523TH\""},{"id":"GlycanIUPAC_T286","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G36445ON\""},{"id":"GlycanIUPAC_T287","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G67363FK\""},{"id":"GlycanIUPAC_T288","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G17562KT\""},{"id":"GlycanIUPAC_T289","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G24774YJ\""},{"id":"GlycanIUPAC_T290","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G32162UO\""},{"id":"GlycanIUPAC_T291","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G89163RR\""},{"id":"GlycanIUPAC_T292","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G99522DY\""},{"id":"GlycanIUPAC_T293","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G59246IF\""},{"id":"GlycanIUPAC_T294","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G95321NT\""},{"id":"GlycanIUPAC_T295","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G17531ZI\""},{"id":"GlycanIUPAC_T296","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G54322SU\""},{"id":"GlycanIUPAC_T297","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G72010DO\""},{"id":"GlycanIUPAC_T298","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G44269EP\""},{"id":"GlycanIUPAC_T299","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G57335AD\""},{"id":"GlycanIUPAC_T300","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G60837LL\""},{"id":"GlycanIUPAC_T301","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G61929XX\""},{"id":"GlycanIUPAC_T302","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G88747RA\""},{"id":"GlycanIUPAC_T303","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G47955HA\""},{"id":"GlycanIUPAC_T304","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G60982WS\""},{"id":"GlycanIUPAC_T305","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G37035KG\""},{"id":"GlycanIUPAC_T306","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G46297FI\""},{"id":"GlycanIUPAC_T307","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G35475KI\""},{"id":"GlycanIUPAC_T308","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G29771JN\""},{"id":"GlycanIUPAC_T309","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G61285YR\""},{"id":"GlycanIUPAC_T310","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G54785MW\""},{"id":"GlycanIUPAC_T311","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G53039GT\""},{"id":"GlycanIUPAC_T312","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G00601HK\""},{"id":"GlycanIUPAC_T313","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G10485IJ\""},{"id":"GlycanIUPAC_T314","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G16393IB\""},{"id":"GlycanIUPAC_T315","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G98436FZ\""},{"id":"GlycanIUPAC_T316","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G18825IA\""},{"id":"GlycanIUPAC_T317","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G61281HQ\""},{"id":"GlycanIUPAC_T318","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G07798TI\""},{"id":"GlycanIUPAC_T319","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G55921QA\""},{"id":"GlycanIUPAC_T320","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G99066DL\""},{"id":"GlycanIUPAC_T321","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G33451PQ\""},{"id":"GlycanIUPAC_T322","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G02111XU\""},{"id":"GlycanIUPAC_T323","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G85193OM\""},{"id":"GlycanIUPAC_T324","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G89174YQ\""},{"id":"GlycanIUPAC_T325","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G28802LE\""},{"id":"GlycanIUPAC_T326","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G56061JK\""},{"id":"GlycanIUPAC_T327","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G68941BC\""},{"id":"GlycanIUPAC_T328","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G55436FC\""},{"id":"GlycanIUPAC_T329","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G24002PU\""},{"id":"GlycanIUPAC_T330","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G61387SV\""},{"id":"GlycanIUPAC_T331","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G31834HW\""},{"id":"GlycanIUPAC_T332","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G35324RT\""},{"id":"GlycanIUPAC_T333","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G34803QO\""},{"id":"GlycanIUPAC_T334","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G92898FF\""},{"id":"GlycanIUPAC_T335","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G01318VX\""},{"id":"GlycanIUPAC_T336","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G83200MX\""},{"id":"GlycanIUPAC_T337","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G56286UC\""},{"id":"GlycanIUPAC_T338","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G07304QA\""},{"id":"GlycanIUPAC_T339","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G06868OU\""},{"id":"GlycanIUPAC_T340","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G12647BS\""},{"id":"GlycanIUPAC_T341","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G51841DF\""},{"id":"GlycanIUPAC_T342","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G32122AJ\""},{"id":"GlycanIUPAC_T343","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G41125MN\""},{"id":"GlycanIUPAC_T344","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G16093XS\""},{"id":"GlycanIUPAC_T345","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G62425IX\""},{"id":"GlycanIUPAC_T346","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G15673TO\""},{"id":"GlycanIUPAC_T347","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G32857IK\""},{"id":"GlycanIUPAC_T348","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G60047CJ\""},{"id":"GlycanIUPAC_T349","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G55718ZB\""},{"id":"GlycanIUPAC_T350","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G88355ZE\""},{"id":"GlycanIUPAC_T351","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G11283PA\""},{"id":"GlycanIUPAC_T352","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G71737IZ\""},{"id":"GlycanIUPAC_T353","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G60912WZ\""},{"id":"GlycanIUPAC_T354","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G99655SO\""},{"id":"GlycanIUPAC_T355","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G10300TW\""},{"id":"GlycanIUPAC_T356","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G89509FL\""},{"id":"GlycanIUPAC_T357","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G31465TH\""},{"id":"GlycanIUPAC_T358","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G94101LU\""},{"id":"GlycanIUPAC_T359","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G38610BB\""},{"id":"GlycanIUPAC_T360","span":{"begin":724,"end":727},"obj":"\"http://rdf.glycoinfo.org/glycan/G85893UF\""},{"id":"GlycanIUPAC_T361","span":{"begin":724,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G44066MP\""},{"id":"GlycanIUPAC_T362","span":{"begin":724,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G64135HS\""},{"id":"GlycanIUPAC_T363","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G31332AK\""},{"id":"GlycanIUPAC_T364","span":{"begin":728,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G79003DV\""},{"id":"GlycanIUPAC_T365","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G87514NT\""},{"id":"GlycanIUPAC_T366","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G22611DV\""},{"id":"GlycanIUPAC_T367","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G42401YF\""},{"id":"GlycanIUPAC_T368","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G62324YU\""},{"id":"GlycanIUPAC_T369","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G58431IT\""},{"id":"GlycanIUPAC_T370","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G09016GK\""},{"id":"GlycanIUPAC_T371","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G34898TQ\""},{"id":"GlycanIUPAC_T372","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G46532QF\""},{"id":"GlycanIUPAC_T373","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G90454DJ\""},{"id":"GlycanIUPAC_T374","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G42324EF\""},{"id":"GlycanIUPAC_T375","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G16770TC\""},{"id":"GlycanIUPAC_T376","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G16690RG\""},{"id":"GlycanIUPAC_T377","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G67017FS\""},{"id":"GlycanIUPAC_T378","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G06272WO\""},{"id":"GlycanIUPAC_T379","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G02869JM\""},{"id":"GlycanIUPAC_T380","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G10405YX\""},{"id":"GlycanIUPAC_T381","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G03811CG\""},{"id":"GlycanIUPAC_T382","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G21647YB\""},{"id":"GlycanIUPAC_T383","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G99463WU\""},{"id":"GlycanIUPAC_T384","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G04174LV\""},{"id":"GlycanIUPAC_T385","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G44824AP\""},{"id":"GlycanIUPAC_T386","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G96945FZ\""},{"id":"GlycanIUPAC_T387","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G06313MM\""},{"id":"GlycanIUPAC_T388","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G81587VF\""},{"id":"GlycanIUPAC_T389","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G81556FU\""},{"id":"GlycanIUPAC_T390","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G02452VK\""},{"id":"GlycanIUPAC_T391","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G66219IC\""},{"id":"GlycanIUPAC_T392","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G53328JP\""},{"id":"GlycanIUPAC_T393","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G21259BQ\""},{"id":"GlycanIUPAC_T394","span":{"begin":724,"end":741},"obj":"\"http://rdf.glycoinfo.org/glycan/G02231DC\""},{"id":"GlycanIUPAC_T395","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G23425WZ\""},{"id":"GlycanIUPAC_T396","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G02874VH\""},{"id":"GlycanIUPAC_T397","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G99699DW\""},{"id":"GlycanIUPAC_T398","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G22074RM\""},{"id":"GlycanIUPAC_T399","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G48535VZ\""},{"id":"GlycanIUPAC_T400","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G39738WL\""},{"id":"GlycanIUPAC_T401","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G42313WU\""},{"id":"GlycanIUPAC_T402","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G00393CK\""},{"id":"GlycanIUPAC_T403","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G42649EX\""},{"id":"GlycanIUPAC_T404","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G46880SB\""},{"id":"GlycanIUPAC_T405","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G75599IR\""},{"id":"GlycanIUPAC_T406","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G58985MU\""},{"id":"GlycanIUPAC_T407","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G92517PO\""},{"id":"GlycanIUPAC_T408","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G88512YL\""},{"id":"GlycanIUPAC_T409","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G41473NX\""},{"id":"GlycanIUPAC_T410","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G71089RB\""},{"id":"GlycanIUPAC_T411","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G73485GZ\""},{"id":"GlycanIUPAC_T412","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G61406KC\""},{"id":"GlycanIUPAC_T413","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G34412GZ\""},{"id":"GlycanIUPAC_T414","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G67209FP\""},{"id":"GlycanIUPAC_T415","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G61442IL\""},{"id":"GlycanIUPAC_T416","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G93729MV\""},{"id":"GlycanIUPAC_T417","span":{"begin":728,"end":734},"obj":"\"http://rdf.glycoinfo.org/glycan/G92144AE\""},{"id":"GlycanIUPAC_T418","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G41652MJ\""},{"id":"GlycanIUPAC_T419","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G20761YC\""},{"id":"GlycanIUPAC_T420","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G19807HM\""},{"id":"GlycanIUPAC_T421","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G20351TE\""},{"id":"GlycanIUPAC_T422","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G71957MR\""},{"id":"GlycanIUPAC_T423","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G59040AE\""},{"id":"GlycanIUPAC_T424","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G14987PW\""},{"id":"GlycanIUPAC_T425","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G95064PC\""},{"id":"GlycanIUPAC_T426","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G39143AQ\""},{"id":"GlycanIUPAC_T427","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G65149OO\""},{"id":"GlycanIUPAC_T428","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G02766SY\""},{"id":"GlycanIUPAC_T429","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G26019KJ\""},{"id":"GlycanIUPAC_T430","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G36429CZ\""},{"id":"GlycanIUPAC_T431","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G89633TP\""},{"id":"GlycanIUPAC_T432","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G28494FO\""},{"id":"GlycanIUPAC_T433","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G06219CP\""},{"id":"GlycanIUPAC_T434","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G44237SM\""},{"id":"GlycanIUPAC_T435","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G57948RL\""},{"id":"GlycanIUPAC_T436","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G64016DN\""},{"id":"GlycanIUPAC_T437","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G14536PC\""},{"id":"GlycanIUPAC_T438","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G14356FW\""},{"id":"GlycanIUPAC_T439","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G34565UO\""},{"id":"GlycanIUPAC_T440","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G67124MW\""},{"id":"GlycanIUPAC_T441","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G71457ZU\""},{"id":"GlycanIUPAC_T442","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G55228VZ\""},{"id":"GlycanIUPAC_T443","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G31034MJ\""},{"id":"GlycanIUPAC_T444","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G25776IP\""},{"id":"GlycanIUPAC_T445","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G64442BV\""},{"id":"GlycanIUPAC_T446","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G57018LE\""},{"id":"GlycanIUPAC_T447","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G61761GX\""},{"id":"GlycanIUPAC_T448","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G76318UX\""},{"id":"GlycanIUPAC_T449","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G61906ER\""},{"id":"GlycanIUPAC_T450","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G68723GR\""},{"id":"GlycanIUPAC_T451","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G19540LE\""},{"id":"GlycanIUPAC_T452","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G74944PO\""},{"id":"GlycanIUPAC_T453","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G89489ZJ\""},{"id":"GlycanIUPAC_T454","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G04434YU\""},{"id":"GlycanIUPAC_T455","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G21450PB\""},{"id":"GlycanIUPAC_T456","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G93629QY\""},{"id":"GlycanIUPAC_T457","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G02603TR\""},{"id":"GlycanIUPAC_T458","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G40280JP\""},{"id":"GlycanIUPAC_T459","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G95259IC\""},{"id":"GlycanIUPAC_T460","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G26900FE\""},{"id":"GlycanIUPAC_T461","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G21346KK\""},{"id":"GlycanIUPAC_T462","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G62509FF\""},{"id":"GlycanIUPAC_T463","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G83932AK\""},{"id":"GlycanIUPAC_T464","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G96978IB\""},{"id":"GlycanIUPAC_T465","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G34275DN\""},{"id":"GlycanIUPAC_T466","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G07071JF\""},{"id":"GlycanIUPAC_T467","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G80639QD\""},{"id":"GlycanIUPAC_T468","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G99460PJ\""},{"id":"GlycanIUPAC_T469","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G22024BZ\""},{"id":"GlycanIUPAC_T470","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G74097ZY\""},{"id":"GlycanIUPAC_T471","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G84439YP\""},{"id":"GlycanIUPAC_T472","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G52207WQ\""},{"id":"GlycanIUPAC_T473","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G90695MS\""},{"id":"GlycanIUPAC_T474","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G50398QX\""},{"id":"GlycanIUPAC_T475","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G12166ZT\""},{"id":"GlycanIUPAC_T476","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G48368BR\""},{"id":"GlycanIUPAC_T477","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G57407RW\""},{"id":"GlycanIUPAC_T478","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G00386TY\""},{"id":"GlycanIUPAC_T479","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G18723JK\""},{"id":"GlycanIUPAC_T480","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G93757OR\""},{"id":"GlycanIUPAC_T481","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G29006SI\""},{"id":"GlycanIUPAC_T482","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G03099OQ\""},{"id":"GlycanIUPAC_T483","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G53739OW\""},{"id":"GlycanIUPAC_T484","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G70440ZO\""},{"id":"GlycanIUPAC_T485","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G29951RR\""},{"id":"GlycanIUPAC_T486","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G58402TI\""},{"id":"GlycanIUPAC_T487","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G39875TP\""},{"id":"GlycanIUPAC_T488","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G83439QV\""},{"id":"GlycanIUPAC_T489","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G41762RC\""},{"id":"GlycanIUPAC_T490","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G91604UI\""},{"id":"GlycanIUPAC_T491","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G88447WE\""},{"id":"GlycanIUPAC_T492","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G93634BS\""},{"id":"GlycanIUPAC_T493","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G02587BH\""},{"id":"GlycanIUPAC_T494","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G43511MX\""},{"id":"GlycanIUPAC_T495","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G64958DH\""},{"id":"GlycanIUPAC_T496","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G30384TR\""},{"id":"GlycanIUPAC_T497","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G15624EX\""},{"id":"GlycanIUPAC_T498","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G22706ST\""},{"id":"GlycanIUPAC_T499","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G57408PI\""},{"id":"GlycanIUPAC_T500","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G86403XX\""},{"id":"GlycanIUPAC_T501","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G78043YB\""},{"id":"GlycanIUPAC_T502","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G18952JK\""},{"id":"GlycanIUPAC_T503","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G49020ND\""},{"id":"GlycanIUPAC_T504","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G63590YW\""},{"id":"GlycanIUPAC_T505","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G22793KS\""},{"id":"GlycanIUPAC_T506","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G64134SS\""},{"id":"GlycanIUPAC_T507","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G17338HY\""},{"id":"GlycanIUPAC_T508","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G99745XF\""},{"id":"GlycanIUPAC_T509","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G27782HN\""},{"id":"GlycanIUPAC_T510","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G57496DC\""},{"id":"GlycanIUPAC_T511","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G93169WB\""},{"id":"GlycanIUPAC_T512","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G05518TD\""},{"id":"GlycanIUPAC_T513","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G62603DN\""},{"id":"GlycanIUPAC_T514","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G59574FS\""},{"id":"GlycanIUPAC_T515","span":{"begin":1495,"end":1498},"obj":"\"http://rdf.glycoinfo.org/glycan/G47567WC\""}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    performance-test

    {"project":"performance-test","denotations":[{"id":"PD-UBERON-AE-B_T1","span":{"begin":69,"end":76},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T2","span":{"begin":194,"end":201},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T3","span":{"begin":316,"end":323},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T4","span":{"begin":462,"end":469},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T5","span":{"begin":502,"end":509},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T6","span":{"begin":1568,"end":1575},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T7","span":{"begin":1902,"end":1909},"obj":"http://purl.obolibrary.org/obo/UBERON_0001155"},{"id":"PD-UBERON-AE-B_T8","span":{"begin":470,"end":476},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"PD-UBERON-AE-B_T9","span":{"begin":1576,"end":1582},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"PD-UBERON-AE-B_T10","span":{"begin":1673,"end":1679},"obj":"http://purl.obolibrary.org/obo/UBERON_0000344"},{"id":"PD-UBERON-AE-B_T11","span":{"begin":331,"end":338},"obj":"http://purl.obolibrary.org/obo/UBERON_0000479"},{"id":"PD-UBERON-AE-B_T12","span":{"begin":462,"end":476},"obj":"http://purl.obolibrary.org/obo/UBERON_0000317"},{"id":"PD-UBERON-AE-B_T13","span":{"begin":1568,"end":1582},"obj":"http://purl.obolibrary.org/obo/UBERON_0000317"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    DisGeNET

    {"project":"DisGeNET","denotations":[{"id":"T0","span":{"begin":53,"end":64},"obj":"gene:10164"},{"id":"T1","span":{"begin":69,"end":100},"obj":"disease:C0279639"}],"relations":[{"id":"R1","pred":"associated_with","subj":"T0","obj":"T1"}],"namespaces":[{"prefix":"gene","uri":"http://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"disease","uri":"http://purl.bioontology.org/ontology/MEDLINEPLUS/"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    Anatomy-MAT

    {"project":"Anatomy-MAT","denotations":[{"id":"T2","span":{"begin":194,"end":201},"obj":"Body_part"},{"id":"T3","span":{"begin":316,"end":323},"obj":"Body_part"},{"id":"T4","span":{"begin":462,"end":469},"obj":"Body_part"},{"id":"T5","span":{"begin":502,"end":509},"obj":"Body_part"},{"id":"T6","span":{"begin":1568,"end":1575},"obj":"Body_part"},{"id":"T7","span":{"begin":1902,"end":1909},"obj":"Body_part"},{"id":"T1","span":{"begin":69,"end":76},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A2","pred":"mat_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A3","pred":"mat_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A4","pred":"mat_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A5","pred":"mat_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A6","pred":"mat_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A7","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    mondo_disease

    {"project":"mondo_disease","denotations":[{"id":"T1","span":{"begin":69,"end":100},"obj":"Disease"},{"id":"T2","span":{"begin":343,"end":358},"obj":"Disease"},{"id":"T3","span":{"begin":502,"end":525},"obj":"Disease"},{"id":"T4","span":{"begin":587,"end":611},"obj":"Disease"},{"id":"T5","span":{"begin":1503,"end":1527},"obj":"Disease"},{"id":"T6","span":{"begin":1599,"end":1613},"obj":"Disease"},{"id":"T7","span":{"begin":1720,"end":1735},"obj":"Disease"},{"id":"T8","span":{"begin":1806,"end":1829},"obj":"Disease"},{"id":"T9","span":{"begin":1902,"end":1925},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005007"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0004970"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0002271"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0004957"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0004957"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0004970"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0004970"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0004957"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0002271"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    Glycan-GlyCosmos

    {"project":"Glycan-GlyCosmos","denotations":[{"id":"T1","span":{"begin":728,"end":734},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    sentences

    {"project":"sentences","denotations":[{"id":"TextSentencer_T1","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"TextSentencer_T2","span":{"begin":102,"end":217},"obj":"Sentence"},{"id":"TextSentencer_T3","span":{"begin":218,"end":406},"obj":"Sentence"},{"id":"TextSentencer_T4","span":{"begin":407,"end":612},"obj":"Sentence"},{"id":"TextSentencer_T5","span":{"begin":613,"end":858},"obj":"Sentence"},{"id":"TextSentencer_T6","span":{"begin":859,"end":1093},"obj":"Sentence"},{"id":"TextSentencer_T7","span":{"begin":1094,"end":1296},"obj":"Sentence"},{"id":"TextSentencer_T8","span":{"begin":1297,"end":1440},"obj":"Sentence"},{"id":"TextSentencer_T9","span":{"begin":1441,"end":1614},"obj":"Sentence"},{"id":"TextSentencer_T10","span":{"begin":1615,"end":1736},"obj":"Sentence"},{"id":"TextSentencer_T11","span":{"begin":1737,"end":1926},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"T2","span":{"begin":102,"end":217},"obj":"Sentence"},{"id":"T3","span":{"begin":218,"end":406},"obj":"Sentence"},{"id":"T4","span":{"begin":407,"end":612},"obj":"Sentence"},{"id":"T5","span":{"begin":613,"end":858},"obj":"Sentence"},{"id":"T6","span":{"begin":859,"end":1093},"obj":"Sentence"},{"id":"T7","span":{"begin":1094,"end":1296},"obj":"Sentence"},{"id":"T8","span":{"begin":1297,"end":1440},"obj":"Sentence"},{"id":"T9","span":{"begin":1441,"end":1614},"obj":"Sentence"},{"id":"T10","span":{"begin":1615,"end":1736},"obj":"Sentence"},{"id":"T11","span":{"begin":1737,"end":1926},"obj":"Sentence"},{"id":"T1","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"T2","span":{"begin":102,"end":217},"obj":"Sentence"},{"id":"T3","span":{"begin":218,"end":406},"obj":"Sentence"},{"id":"T4","span":{"begin":407,"end":612},"obj":"Sentence"},{"id":"T5","span":{"begin":613,"end":858},"obj":"Sentence"},{"id":"T6","span":{"begin":859,"end":1093},"obj":"Sentence"},{"id":"T7","span":{"begin":1094,"end":1296},"obj":"Sentence"},{"id":"T8","span":{"begin":1297,"end":1440},"obj":"Sentence"},{"id":"T9","span":{"begin":1441,"end":1614},"obj":"Sentence"},{"id":"T10","span":{"begin":1615,"end":1736},"obj":"Sentence"},{"id":"T11","span":{"begin":1737,"end":1926},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlyCosmos15-Sentences

    {"project":"GlyCosmos15-Sentences","blocks":[{"id":"T1","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"T2","span":{"begin":102,"end":217},"obj":"Sentence"},{"id":"T3","span":{"begin":218,"end":406},"obj":"Sentence"},{"id":"T4","span":{"begin":407,"end":612},"obj":"Sentence"},{"id":"T5","span":{"begin":613,"end":858},"obj":"Sentence"},{"id":"T6","span":{"begin":859,"end":1093},"obj":"Sentence"},{"id":"T7","span":{"begin":1094,"end":1296},"obj":"Sentence"},{"id":"T8","span":{"begin":1297,"end":1440},"obj":"Sentence"},{"id":"T9","span":{"begin":1441,"end":1614},"obj":"Sentence"},{"id":"T10","span":{"begin":1615,"end":1736},"obj":"Sentence"},{"id":"T11","span":{"begin":1737,"end":1926},"obj":"Sentence"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlyCosmos15-MONDO

    {"project":"GlyCosmos15-MONDO","denotations":[{"id":"T1","span":{"begin":69,"end":100},"obj":"Disease"},{"id":"T2","span":{"begin":343,"end":358},"obj":"Disease"},{"id":"T3","span":{"begin":502,"end":525},"obj":"Disease"},{"id":"T4","span":{"begin":587,"end":611},"obj":"Disease"},{"id":"T5","span":{"begin":1503,"end":1527},"obj":"Disease"},{"id":"T6","span":{"begin":1599,"end":1613},"obj":"Disease"},{"id":"T7","span":{"begin":1720,"end":1735},"obj":"Disease"},{"id":"T8","span":{"begin":1806,"end":1829},"obj":"Disease"},{"id":"T9","span":{"begin":1902,"end":1925},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"MONDO:0005007"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"MONDO:0004970"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"MONDO:0002271"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"MONDO:0004957"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"MONDO:0004957"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"MONDO:0004970"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"MONDO:0004970"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"MONDO:0004957"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"MONDO:0002271"}],"namespaces":[{"prefix":"MONDO","uri":"http://purl.obolibrary.org/obo/MONDO_"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlyCosmos15-UBERON

    {"project":"GlyCosmos15-UBERON","denotations":[{"id":"T1","span":{"begin":462,"end":476},"obj":"Body_part"},{"id":"T2","span":{"begin":1568,"end":1582},"obj":"Body_part"},{"id":"T3","span":{"begin":1673,"end":1679},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000317"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000317"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000344"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlyCosmos15-FMA

    {"project":"GlyCosmos15-FMA","denotations":[{"id":"T1","span":{"begin":331,"end":338},"obj":"Body_part"},{"id":"T2","span":{"begin":462,"end":476},"obj":"Body_part"},{"id":"T3","span":{"begin":1568,"end":1582},"obj":"Body_part"},{"id":"T4","span":{"begin":1673,"end":1679},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"db_id","subj":"T1","obj":"FMA:9637"},{"id":"A2","pred":"db_id","subj":"T2","obj":"FMA:14984"},{"id":"A3","pred":"db_id","subj":"T3","obj":"FMA:14984"},{"id":"A4","pred":"db_id","subj":"T4","obj":"FMA:85355"}],"namespaces":[{"prefix":"FMA","uri":"http://purl.org/sig/ont/fma/fma"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlyCosmos15-MAT

    {"project":"GlyCosmos15-MAT","denotations":[{"id":"T1","span":{"begin":69,"end":76},"obj":"Body_part"},{"id":"T2","span":{"begin":194,"end":201},"obj":"Body_part"},{"id":"T3","span":{"begin":316,"end":323},"obj":"Body_part"},{"id":"T4","span":{"begin":462,"end":469},"obj":"Body_part"},{"id":"T5","span":{"begin":502,"end":509},"obj":"Body_part"},{"id":"T6","span":{"begin":1568,"end":1575},"obj":"Body_part"},{"id":"T7","span":{"begin":1902,"end":1909},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"mat_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A2","pred":"mat_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A3","pred":"mat_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A4","pred":"mat_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A5","pred":"mat_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A6","pred":"mat_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MAT_0000526"},{"id":"A7","pred":"mat_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MAT_0000526"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    GlyCosmos15-Glycan

    {"project":"GlyCosmos15-Glycan","denotations":[{"id":"T1","span":{"begin":728,"end":734},"obj":"Glycan"}],"attributes":[{"id":"A1","pred":"glycosmos_id","subj":"T1","obj":"https://glycosmos.org/glycans/show/G39738WL"},{"id":"A2","pred":"image","subj":"T1","obj":"https://api.glycosmos.org/wurcs2image/latest/png/binary/G39738WL"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}

    Anatomy-UBERON

    {"project":"Anatomy-UBERON","denotations":[{"id":"T1","span":{"begin":462,"end":476},"obj":"Body_part"},{"id":"T2","span":{"begin":1568,"end":1582},"obj":"Body_part"},{"id":"T3","span":{"begin":1673,"end":1679},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"uberon_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/UBERON_0000317"},{"id":"A2","pred":"uberon_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/UBERON_0000317"},{"id":"A3","pred":"uberon_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/UBERON_0000344"}],"text":"Ectopic expression of a GlcNAc 6-O-sulfotransferase, GlcNAc6ST-2, in colonic mucinous adenocarcinoma.\nThe content of sulfated glycans having 6-O-sulfated GlcNAc residues alters in the course of colonic carcinogenesis. We previously characterized two GlcNAc 6-O-sulfotransferases (SulTs), SulT-a and -b, expressed in colonic normal tissues and adenocarcinomas [Seko et al. (2000) Glycobiology, 10, 919-929]. Levels of the enzymatic activities of SulT-a in normal colonic mucosa are higher than those in colonic adenocarcinomas, and the enzymatic activities of SulT-b are detected only in mucinous adenocarcinomas. To determine which GlcNAc 6-O-SulTs cloned so far correspond to SulT-a and -b, we expressed seven enzymes of a Gal/GalNAc/GlcNAc 6-O-SulT family in COS-7 cells and examined their substrate specificities in comparison with those of SulT-a and -b. GlcNAc6ST-2 (HEC-GlcNAc6ST, LSST, or GST-3) can recognize GlcNAcbeta1--\u003e3GalNAcalpha1-O-pNP as a good acceptor as well as other O-linked- and N-linked-type oligosaccharides, and its substrate specificity was similar to that of SulT-b. GlcNAc6ST-3(I-GlcNAc6ST or GST-4alpha) preferred Galbeta1--\u003e3(GlcNAcbeta1--\u003e6)GalNAcalpha1-O-pNP as an acceptor to the other oligosaccharides examined, and its specificity was similar to that of SulT-a. To confirm these correspondences, we further performed quantitative analyses of transcripts for GlcNAc6ST-2 and -3 genes by competitive RT-PCR. As a result, GlcNAc6ST-2 gene was expressed in almost all the mucinous adenocarcinomas examined and hardly expressed in normal colonic mucosa and nonmucinous adenocarcinoma. Expression levels of transcript for GlcNAc6ST-3 in normal mucosa were significantly higher than those in adenocarcinomas. From these results, it was indicated that GlcNAc6ST-2 corresponds to mucinous adenocarcinoma-specific SulT-b and that expression of GlcNAc6ST-3 is down-regulated in colonic adenocarcinomas."}